151 related articles for article (PubMed ID: 18326533)
1. Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
van Vollenhoven RF;
Rheumatology (Oxford); 2008 Jul; 47(7):1106-7; author reply 1107. PubMed ID: 18326533
[No Abstract] [Full Text] [Related]
2. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
3. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
Kulp W; Greiner W; Graf von der Schulenburg JM
Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
[TBL] [Abstract][Full Text] [Related]
5. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
Metcalfe S; Moodie P; Grocott R; Wilkinson T
N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
[No Abstract] [Full Text] [Related]
6. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
Lindgren P; Geborek P; Kobelt G
Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
[TBL] [Abstract][Full Text] [Related]
7. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
8. Biologicals for rheumatoid arthritis.
Tugwell P; Singh JA; Wells GA
BMJ; 2011 Jul; 343():d4027. PubMed ID: 21798970
[No Abstract] [Full Text] [Related]
9. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
[TBL] [Abstract][Full Text] [Related]
10. [Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].
Z Rheumatol; 2000 Aug; 59(4):291-2. PubMed ID: 11013988
[No Abstract] [Full Text] [Related]
11. Patient access to rheumatoid arthritis treatments.
Jönsson B
Eur J Health Econ; 2008 Jan; 8 Suppl 2():S35-8. PubMed ID: 18157679
[TBL] [Abstract][Full Text] [Related]
12. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
Haraoui B
J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
[No Abstract] [Full Text] [Related]
14. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
15. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
17. Economic consequences of established rheumatoid arthritis and its treatment.
Kavanaugh A
Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):929-42. PubMed ID: 17870036
[TBL] [Abstract][Full Text] [Related]
18. Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result.
Welsing PM; Severens JL; Laan RF
Rheumatology (Oxford); 2003 Dec; 42(12):1574-5; author reply 1573-4. PubMed ID: 14645870
[No Abstract] [Full Text] [Related]
19. Are we coming to terms with tumor necrosis factor inhibition in pregnancy?
Salmon JE; Alpert D
Arthritis Rheum; 2006 Aug; 54(8):2353-5. PubMed ID: 16868990
[No Abstract] [Full Text] [Related]
20. Do we really need five TNF antagonists?
Ruderman EM
Rheumatology (Oxford); 2010 Jun; 49(6):1028-9. PubMed ID: 20172993
[No Abstract] [Full Text] [Related]
[Next] [New Search]
